UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM
___________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
___________________________________________
(Exact name of registrant as specified in its charter)
___________________________________________
|
|
|
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (
_________________________________________________________
(Former name or former address, if changed since last report)
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange |
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
|
|
|
|
|
Section 2 | Financial Information. |
|
|
Item 2.02 | Results of Operations and Financial Condition. |
On February 11, 2021, CryoLife, Inc. (“CryoLife” or the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2020. CryoLife hereby incorporates by reference herein the information set forth in its press release dated February 11, 2021, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of CryoLife have continued unchanged since such date.
The information provided pursuant to this Item 2.02 is to be considered “furnished” pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of CryoLife’s reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing.
Except for the historical information contained in this report, the statements made by CryoLife are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. CryoLife’s future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to “Risk Factors” contained in CryoLife’s most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as well as in the press release attached as Exhibit 99.1 hereto. CryoLife disclaims any obligation or duty to update or modify these forward-looking statements.
|
|
|
|
|
|
Section 9 | Financial Statements and Exhibits. |
|
|
Item 9.01(d) | Exhibits. |
(d)Exhibits.
|
|
Exhibit Number | Description |
99.1* | Press Release dated February 11, 2021
|
*This exhibit is furnished, not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 11, 2021
|
|
|
|
|
| CRYOLIFE, INC. |
|
|
|
|
|
| By: | /s/ D. Ashley Lee |
|
| Name: | D. Ashley Lee |
|
| Title: | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
|
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contacts:
|
|
|
|
CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 |
Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 investors@cryolife.com |
CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results
Fourth Quarter and Recent Business Highlights:
|
· |
Achieved total revenues of $67.9 million in the fourth quarter 2020 versus $69.7 million in the fourth quarter of 2019 |
|
o |
Total revenues decreased 3% on a GAAP basis and 5% on a non-GAAP proforma constant currency basis versus fourth quarter 2019 |
|
o |
Excluding TMR, fourth quarter revenues decreased 2% on a non-GAAP proforma basis and 3% on a non-GAAP proforma constant currency basis versus fourth quarter 2019 |
|
· |
Achieved net loss of ($3.5) million, or ($0.09) per share |
|
· |
Achieved non-GAAP net income of $7.9 million, or $0.20 per share |
ATLANTA, GA – (February 11, 2021) – CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the fourth quarter and full year ended December 31, 2020.
“Despite the ongoing impact of COVID-19 on our business, we were able to generate solid quarterly results and advance our key operational goals. We completed the integration of Ascyrus, launched our newest JOTEC products, and made good progress on enrollment in our PROACT Xa clinical trial,” commented Pat Mackin, Chairman, President, and Chief Executive Officer. “Additionally, our manufacturing facilities continued to run at near capacity and our supply chain remains largely intact. We also continued to invest in our commercial channels and R&D programs related to products that we believe will deliver revenue in 2021 and 2022, including our regulatory approvals for U.S. PerClot, BioGlue China and PROACT Mitral. We also progressed in our efforts to obtain regulatory approval for Ascyrus in the US and other countries. These fundamental drivers, combined with declining COVID-19 infection rates and accelerating vaccination programs in various regions around the world, make us optimistic that the second half of 2021 should be the start of a prolonged period of growth for CryoLife.”
Page 1 of 8
Fourth Quarter 2020 Financial Results
Total revenues for the fourth quarter of 2020 were $67.9 million, reflecting a decrease of 3% on a GAAP basis and a decrease of 5% on a non-GAAP proforma constant currency basis, both compared to the fourth quarter of 2019. Revenue performance across all product lines reflected the impact of the COVID-19 pandemic on the number of procedures using our products.
Net loss for the fourth quarter of 2020 was $(3.5) million, or $(0.09) per fully diluted common share, compared to net loss of ($0.7) million, or ($0.02) per fully diluted common share for the fourth quarter of 2019. Non-GAAP net income for the fourth quarter of 2020 was $7.9 million, or $0.20 per fully diluted common share, compared to non-GAAP net income of $4.2 million, or $0.11 per fully diluted common share for the fourth quarter of 2019. Loss for the fourth quarter of 2020 includes pretax expense of $4.8 million of business development costs primarily related to the Ascyrus acquisition, partially offset by pretax benefit of $1.2 million resulting from a change in the Company’s paid time off policy and a non-cash pretax benefit of $3.0 million related to the reversal of performance-based stock compensation because financial targets were not met due to the impact of COVID-19.
Full Year 2020 Financial Results
Total revenues for 2020 were $253.2 million, reflecting a decrease of 8% on both a GAAP and non-GAAP proforma constant currency basis, both compared to the full year of 2019. Revenue performance across all product lines reflected the impact of the COVID-19 pandemic on the number of procedures using our products.
Net loss for 2020 was ($16.7) million, or ($0.44) per fully diluted common share, compared to net income of $1.7 million, or $0.05 per fully diluted common share for the full year of 2019. Non-GAAP net income for the full year of 2020 was $9.7 million, or $0.25 per fully diluted common share, compared to non-GAAP net income of $12.9 million, or $0.34 per fully diluted common share for the full year of 2019. Loss for the full year of 2020 includes pretax expense of $12.3 million of business development costs primarily related to the Ascyrus and Endospan transactions, partially offset by pretax benefit of $1.2 million resulting from a change in the Company’s paid time off policy and a non-cash pretax benefit of $3.0 million related to the reversal of performance-based stock compensation because financial targets were not met due to the impact of COVID-19.
The independent registered public accounting firm's audit report with respect to the Company's fiscal year-end financial statements will not be issued until the Company completes its annual report on Form 10-K. Accordingly, the financial results reported in this earnings release are preliminary pending completion of the audit.
2021 Financial Outlook
Due to continued uncertainties resulting from the COVID-19 global pandemic, the Company is not issuing 2021 financial guidance at this time.
The Company's financial performance for 2021 is subject to the risks identified below.
Page 2 of 8
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP net income and non-GAAP EBITDA results exclude (as applicable) business development, integration, and severance expense; depreciation and amortization expense; interest income and expense; non-cash interest expense; loss on foreign currency revaluation; stock-based compensation expense; corporate rebranding expense; and income tax expense (benefit). The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company has excluded the impact of changes in currency exchange from certain revenues to evaluate growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, February 11, 2021 at 4:30 p.m. ET to discuss the results followed by a question and answer session. To listen to the live teleconference, please dial 201-689-8261. A replay of the teleconference will be available through February 18, 2021 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The Conference ID for the replay is 13715710.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Page 3 of 8
Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these foreword-looking statements, which are made as of the date of this press release and reflect the view of management as of the date of this press release. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that, despite the ongoing impact of COVID-19 on our business, we were able to generate solid quarterly results, advance on our key operational goals, and make good progress on enrollment in our PROACT Xa clinical trial; our R&D programs in which we continued to invest in 2020, such as U.S. PerClot, BioGlue China and PROACT Mitral, will deliver revenue in 2021 and 2022, and our fundamental drivers, combined with declining COVID-19 infection rates and accelerating vaccination programs in various regions around the world, starting in the second half of 2021, should lead to a prolonged period of growth for CryoLife. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations, including that the benefits anticipated from the Ascyrus Medical LLC transaction may not be achieved and the continued effects of COVID-19 and government mandates implemented to address the pandemic could adversely impact our results. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2020. CryoLife does not assume any obligation, and expressly disclaims any duty to update any of its forward-looking statements, whether as a result of new information, future events, or otherwise.
Page 4 of 8
CryoLife, Inc. and Subsidiaries
Financial Highlights
(In thousands, except per share data)
|
|
(Unaudited) |
||||||||||
|
|
Three Months Ended |
Twelve Months Ended |
|||||||||
|
|
December 31, |
December 31, |
|||||||||
|
|
2020 |
2019 |
2020 |
2019 |
|||||||
|
Revenues: |
|||||||||||
|
Products |
$ |
50,502 |
$ |
50,193 |
$ |
179,299 |
$ |
197,246 | |||
|
Preservation services |
17,394 | 19,504 | 73,928 | 78,976 | |||||||
|
Total revenues |
67,896 | 69,697 | 253,227 | 276,222 | |||||||
|
|
|||||||||||
|
Cost of products and preservation services: |
|||||||||||
|
Products |
14,050 | 14,001 | 50,128 | 55,022 | |||||||
|
Preservation services |
9,255 | 9,144 | 35,315 | 38,187 | |||||||
|
Total cost of products and preservation services |
23,305 | 23,145 | 85,443 | 93,209 | |||||||
|
|
|||||||||||
|
Gross margin |
44,591 | 46,552 | 167,784 | 183,013 | |||||||
|
|
|||||||||||
|
Operating expenses: |
|||||||||||
|
General, administrative, and marketing |
36,103 | 37,609 | 141,136 | 143,011 | |||||||
|
Research and development |
6,574 | 5,312 | 24,207 | 22,960 | |||||||
|
Total operating expenses |
42,677 | 42,921 | 165,343 | 165,971 | |||||||
|
|
|||||||||||
|
Operating income |
1,914 | 3,631 | 2,441 | 17,042 | |||||||
|
|
|||||||||||
|
Interest expense |
4,718 | 3,626 | 16,698 | 14,886 | |||||||
|
Interest income |
(36) | (130) | (217) | (738) | |||||||
|
Other (income) expense, net |
(2,676) | (1,412) | 3,134 | 1,250 | |||||||
|
|
|||||||||||
|
(Loss) income before income taxes |
(92) | 1,547 | (17,174) | 1,644 | |||||||
|
Income tax expense (benefit) |
3,366 | 2,228 | (492) | (76) | |||||||
|
|
|||||||||||
|
Net (loss) income |
$ |
(3,458) |
$ |
(681) |
$ |
(16,682) |
$ |
1,720 | |||
|
|
|||||||||||
|
(Loss) income per common share: |
|||||||||||
|
Basic |
$ |
(0.09) | (0.02) |
$ |
(0.44) |
$ |
0.05 | ||||
|
Diluted |
$ |
(0.09) | (0.02) |
$ |
(0.44) |
$ |
0.05 | ||||
|
|
|||||||||||
|
Weighted-average common shares outstanding: |
|||||||||||
|
Basic |
38,613 | 37,274 | 37,861 | 37,118 | |||||||
|
Diluted |
38,613 | 37,274 | 37,861 | 37,860 | |||||||
Page 5 of 8
CryoLife, Inc. and Subsidiaries
Financial Highlights
(In thousands)
|
|
(Unaudited) |
(Unaudited) |
|||||||||
|
|
Three Months Ended |
Twelve Months Ended |
|||||||||
|
|
December 31, |
December 31, |
|||||||||
|
|
2020 |
2019 |
2020 |
2019 |
|||||||
|
Products: |
|||||||||||
|
BioGlue |
$ |
17,083 |
$ |
17,777 |
$ |
62,068 |
$ |
68,611 | |||
|
Aortic stents and stent grafts |
17,731 | 16,038 | 61,663 | 64,974 | |||||||
|
On-X |
13,668 | 13,345 | 48,053 | 50,096 | |||||||
|
PhotoFix |
1,113 | 1,002 | 4,169 | 3,754 | |||||||
|
PerClot |
801 | 981 | 2,882 | 3,795 | |||||||
|
CardioGenesis cardiac laser therapy |
106 | 1,050 | 464 | 6,016 | |||||||
|
Total products |
50,502 | 50,193 | 179,299 | 197,246 | |||||||
|
|
|||||||||||
|
Preservation services: |
|||||||||||
|
Cardiac tissue |
9,135 | 10,145 |
$ |
37,893 |
$ |
40,879 | |||||
|
Vascular tissue |
8,195 | 9,359 | 35,852 | 38,097 | |||||||
|
NeoPatch |
64 |
-- |
183 |
-- |
|||||||
|
Total preservation services |
17,394 | 19,504 | 73,928 | 78,976 | |||||||
|
|
|||||||||||
|
Total revenues |
$ |
67,896 |
$ |
69,697 |
$ |
253,227 |
$ |
276,222 | |||
|
|
|||||||||||
|
Revenues: |
|||||||||||
|
U.S. |
$ |
35,103 |
$ |
37,005 |
$ |
138,274 |
$ |
150,553 | |||
|
International |
32,793 | 32,692 | 114,953 | 125,669 | |||||||
|
Total revenues |
$ |
67,896 |
$ |
69,697 |
$ |
253,227 |
$ |
276,222 | |||
|
|
|||||
|
|
December 31, |
December 31, |
|||
|
|
2020 |
2019 |
|||
|
Cash, cash equivalents, and restricted securities |
$ |
61,958 |
$ |
34,294 | |
|
Total current assets |
234,589 | 187,390 | |||
|
Total assets |
789,404 | 605,654 | |||
|
Total current liabilities |
60,468 | 45,195 | |||
|
Total liabilities |
460,691 | 319,958 | |||
|
Shareholders’ equity |
328,713 | 285,696 | |||
Page 6 of 8
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Net (Loss) Income and Diluted (Loss) Income Per Common Share
(In thousands, except per share data)
|
|
(Unaudited) |
(Unaudited) |
|||||||||
|
|
Three Months Ended |
Twelve Months Ended |
|||||||||
|
|
December 31, |
December 31, |
|||||||||
|
|
2020 |
2019 |
2020 |
2019 |
|||||||
|
GAAP: |
|||||||||||
|
(Loss) income before income taxes |
$ |
(92) |
$ |
1,547 |
$ |
(17,174) |
$ |
1,644 | |||
|
Income tax expense (benefit) |
3,366 | 2,228 | (492) | (76) | |||||||
|
Net (loss) income |
$ |
(3,458) |
$ |
(681) |
$ |
(16,682) |
$ |
1,720 | |||
|
|
|||||||||||
|
Diluted (loss) income per common share: |
$ |
(0.09) |
$ |
(0.02) |
$ |
(0.44) |
$ |
0.05 | |||
|
|
|||||||||||
|
Diluted weighted-average common |
|||||||||||
|
shares outstanding |
38,613 | 37,274 | 37,861 | 37,860 | |||||||
|
|
|||||||||||
|
Reconciliation of (loss) income before income taxes, |
|||||||||||
|
GAAP to adjusted net income, non-GAAP |
|||||||||||
|
(Loss) income before income taxes, GAAP |
$ |
(92) |
$ |
1,547 |
$ |
(17,174) |
$ |
1,644 | |||
|
Adjustments: |
|||||||||||
|
Business development, integration, and severance expense |
4,839 | 526 | 12,320 | 3,088 | |||||||
|
Amortization expense |
4,334 | 3,054 | 13,764 | 10,850 | |||||||
|
Non-cash interest expense |
1,395 | 406 | 3,656 | 1,631 | |||||||
|
Corporate rebranding expense |
15 |
-- |
336 |
-- |
|||||||
|
Adjusted income before income taxes, |
|||||||||||
|
non-GAAP |
10,491 | 5,533 | 12,902 | 17,213 | |||||||
|
|
|||||||||||
|
Income tax expense calculated at a |
|||||||||||
|
pro forma tax rate of 25% |
2,623 | 1,383 | 3,226 | 4,303 | |||||||
|
Adjusted net income, non-GAAP |
$ |
7,868 |
$ |
4,150 |
$ |
9,676 |
$ |
12,910 | |||
|
|
|||||||||||
|
Reconciliation of diluted (loss) income per common share, GAAP |
|||||||||||
|
to adjusted diluted income per common share, non-GAAP: |
|||||||||||
|
Diluted (loss) income per common share, GAAP: |
$ |
(0.09) |
$ |
(0.02) |
$ |
(0.44) |
$ |
0.05 | |||
|
Adjustments: |
|||||||||||
|
Business development, integration, and severance expense |
0.12 | 0.02 | 0.32 | 0.08 | |||||||
|
Amortization expense |
0.11 | 0.08 | 0.36 | 0.28 | |||||||
|
Non-cash interest expense |
0.04 | 0.01 | 0.09 | 0.04 | |||||||
|
Effect of 25% pro forma tax rate |
0.09 | 0.05 | 0.10 | (0.01) | |||||||
|
Corporate rebranding expense |
-- |
-- |
0.01 |
-- |
|||||||
|
Tax effect of non-GAAP adjustments |
(0.07) | (0.03) | (0.19) | (0.10) | |||||||
|
Adjusted diluted income per common share, |
|||||||||||
|
non-GAAP: |
$ |
0.20 |
$ |
0.11 |
$ |
0.25 |
$ |
0.34 | |||
|
|
|||||||||||
|
Diluted weighted-average common |
|||||||||||
|
shares outstanding |
39,100 | 37,914 | 38,369 | 37,860 | |||||||
Page 7 of 8
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Revenues and Adjusted EBITDA
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
(Unaudited) |
||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||
|
|
December 31, |
|
December 31, |
||||||||||
|
|
2020 |
|
2019 |
Growth Rate |
|
2020 |
|
2019 |
Growth Rate |
||||
|
Reconciliation of total revenues, GAAP to |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
total revenues, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues, GAAP |
$ |
67,896 |
|
$ |
69,697 |
-3% |
|
$ |
253,227 |
|
$ |
276,222 |
-8% |
|
Including AMDS prior to acquisition |
|
-- |
|
|
547 |
|
|
|
2,088 |
|
|
2,339 |
|
|
Total GAAP revenues including |
|
67,896 |
|
|
70,244 |
-3% |
|
|
255,315 |
|
|
278,561 |
-8% |
|
Impact of changes in currency exchange |
|
-- |
|
|
1,024 |
|
|
|
-- |
|
|
(708) |
|
|
Total constant currency revenues including |
$ |
67,896 |
|
$ |
71,268 |
-5% |
|
$ |
255,315 |
|
$ |
277,853 |
-8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of total revenues, GAAP to |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
total revenues, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues, GAAP |
$ |
67,896 |
|
$ |
69,697 |
-3% |
|
$ |
253,227 |
|
$ |
276,222 |
-8% |
|
Including AMDS prior to acquisition |
|
-- |
|
|
547 |
|
|
|
2,088 |
|
|
2,339 |
|
|
Excluding CardioGenesis cardiac laser therapy |
|
(106) |
|
|
(1,050) |
|
|
|
(464) |
|
|
(6,016) |
|
|
Total GAAP revenues including |
|
67,790 |
|
|
69,194 |
-2% |
|
|
254,851 |
|
|
272,545 |
-6% |
|
Impact of changes in currency exchange |
|
-- |
|
|
1,024 |
|
|
|
-- |
|
|
(708) |
|
|
Total constant currency revenues including |
$ |
67,790 |
|
$ |
70,218 |
-3% |
|
$ |
254,851 |
|
$ |
271,837 |
-6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
|
(Unaudited) |
||||||||
|
|
Three Months Ended |
|
|
Twelve Months Ended |
||||||||
|
|
December 31, |
|
|
December 31, |
||||||||
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
||||
|
Reconciliation of net (loss) income, GAAP to |
|
|
|
|
|
|
|
|
|
|
|
|
|
adjusted EBITDA, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income, GAAP |
$ |
(3,458) |
|
$ |
(681) |
|
|
$ |
(16,682) |
|
$ |
1,720 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
5,894 |
|
|
5,060 |
|
|
|
20,712 |
|
|
18,317 |
|
Interest expense |
|
4,718 |
|
|
3,626 |
|
|
|
16,698 |
|
|
14,886 |
|
Business development, integration, and severance expense |
|
4,839 |
|
|
526 |
|
|
|
12,320 |
|
|
3,088 |
|
Stock-based compensation expense |
|
(520) |
|
|
2,218 |
|
|
|
6,912 |
|
|
8,799 |
|
Corporate rebranding expense |
|
15 |
|
|
-- |
|
|
|
336 |
|
|
-- |
|
Interest income |
|
(36) |
|
|
(130) |
|
|
|
(217) |
|
|
(738) |
|
Income tax expense (benefit) |
|
3,366 |
|
|
2,228 |
|
|
|
(492) |
|
|
(76) |
|
(Income) loss on foreign currency revaluation |
|
(2,688) |
|
|
(1,437) |
|
|
|
(1,829) |
|
|
1,232 |
|
Adjusted EBITDA, non-GAAP |
$ |
12,130 |
|
$ |
11,410 |
|
|
$ |
37,758 |
|
$ |
47,228 |
Page 8 of 8